hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06319547 id: Soh-Med-24-02-07MS briefTitle: Comparing Outcome of Thoracocentesis and Pigtail Catheter Drainage in Treatment of Patients With Hepatic Hydrothorax overallStatus: RECRUITING date: 2024-02-20 date: 2025-02 date: 2025-03 date: 2024-03-20 date: 2024-03-20 name: Sohag University class: OTHER briefSummary: Hepatic hydrothorax (HH) is a pleural effusion that develops in a patient with cirrhosis and portal hypertension in the absence of cardiopulmonary disease (Lv et al., 2018). Several factors are known to contribute to the development of effusion; the most accepted mechanism of which is the direct delivery of ascitic fluid from the peritoneal cavity to the pleural cavity by "positive" intra-abdominal pressure and a "negative" intrathoracic pressure of the pleural cavity through microscopic congenital diaphragmatic defects (Han et al., 2022). conditions: Hepatic Hydrothorax studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Thoracocentasis measure: percentage of empyema in patients with hepatic hydrothorax after thoracocentesis sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Sohag University hospitals status: RECRUITING city: Sohag country: Egypt name: Magdy M Amin, Professor role: CONTACT lat: 26.55695 lon: 31.69478 hasResults: False
nctId: NCT06319534 id: SGB-ZHENQIU briefTitle: Stellate Ganglion Block in Bulbar Palsy overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-12 date: 2024-12 date: 2024-03-20 date: 2024-03-20 name: Copka Sonpashan class: OTHER_GOV briefSummary: This is a randomized controlled study, including dysphagic patients with bulbar palsy after ischemic stroke who were received in the department of rehabilitation medicine in 3 hospitals in China. All patients are randomly allocated to the observation group or the control group. Both groups are provided with comprehensive rehabilitation. Besides, the observation group additionally undergoes the stellate ganglion block. At admission and after 10-day treatment, video fluoroscopic swallowing study, and penetration-aspiration scale, Functional Oral Intake Scale, Flexible laryngoscope are used to assess swallowing function. conditions: Bulbar Palsy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Comprehensive rehabilitation name: Stellate ganglion block name: Lidocaine Hydrochloride name: placebo injection measure: Penetration-Aspiration Scale measure: Functional Oral Intake Scale measure: Murray secretion severity scale measure: Yale pharyngeal residue severity rating scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06319521 id: SGB-REFLUX briefTitle: Stellate Ganglion Block on Gastroesophageal Reflux Disease overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-12 date: 2024-12 date: 2024-03-20 date: 2024-03-20 name: Copka Sonpashan class: OTHER_GOV briefSummary: The goal of this clinical trial is to explore Clinical Effect of Stellate Ganglion Block on Gastroesophageal Reflux Disease. The main question it aims to answer is:
• Can stellate ganglion block improve gastroesophageal reflux symptoms better on the basis of rehabilitation training? Participants will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given Stellate Ganglion Block once a day additionally. The study lasts 20 days for each participant. Researchers will compare the Gastroesophageal Reflux Disease Questionnaire, Pressure pain threshold, Self-Evaluation Questionnaire for Gastroesophageal Reflux Disease, to see if the Stellate Ganglion Block can help improve the symptom. conditions: Gastroesophageal Reflux Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Rehabilitation therapy name: Stellate ganglion block name: Lidocaine hydrochloride name: Placebo injection measure: Gastroesophageal Reflux Disease Questionnaire measure: Pressure pain threshold measure: Modified Mayo Clinic Dysphagia-30 questionnaire sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06319508 id: SGB-NT briefTitle: Stellate Ganglion Block in Cerebral Palsy overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-12 date: 2024-12 date: 2024-03-20 date: 2024-03-20 name: Copka Sonpashan class: OTHER_GOV briefSummary: The goal of this clinical trial is to test the efficacy of stellate ganglion block in children with cerebral palsy and dysphagia. The main question it aims to answer are:
• Can stellate ganglion block improve the dysphagia of children with cerebral palsy? Participants were randomly divided into two groups, all provided with routine therapy. Based on this, the experimental group was given stellate ganglion block. The video fluoroscopic swallowing study was done to test the swallowing function before and after the study. conditions: Cerebral Palsy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: routine rehabilitation treatment name: Stellate ganglion block name: Lidocaine hydrochloride name: Placebo injection measure: Penetration-Aspiration Scale measure: Swallowing duration measure: Functional Oral Intake Scale sex: ALL minimumAge: 4 Years maximumAge: 7 Years stdAges: CHILD hasResults: False
nctId: NCT06319495 id: SGB-CSVD briefTitle: Stellate Ganglion Block in Patients With Cerebral Small Vessel Disease overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-12 date: 2024-12 date: 2024-03-20 date: 2024-03-20 name: Copka Sonpashan class: OTHER_GOV briefSummary: This is a prospective study conducted on patients with Cerebral Small Vessel Disease, dysphagia and cognitive impairment. They were divided into the comparison group and observation group evenly. All the patients were provided with routine therapy, while the patients in the observation group were given Stellate Ganglion Block. The swallowing function, cognitive function and activities of daily living of the two groups of patients before and after treatment were evaluated by Penetration-Aspiration Scale, Mini-mental state examination and modified Barthel index. conditions: Cerebral Small Vessel Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Rehabilitation therapy name: Stellate ganglion block name: Lidocaine Hydrochloride name: placebo injection measure: Penetration-Aspiration Scale measure: Modified Barthel Index measure: Mini-Mental State Examination measure: Functional Oral Intake Scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06319482 id: Adherence Study briefTitle: The Adherence of Proactive Sleep Apnea Therapy overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-08-01 date: 2025-08-01 date: 2024-03-20 date: 2024-03-20 name: NovaResp Technologies Inc class: INDUSTRY briefSummary: The goal of this clinical trial is to compare the adherence to Positive Airway Pressure (PAP) therapy for newly diagnosed Obstructive Sleep Apnea (OSA) patients. The main question(s) it aims to answer are:
2. To compare health outcomes (AHI, nightly pressure, and patient-reported outcomes) between proactive therapy and conventional APAP therapy. conditions: Obstructive Sleep Apnea studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 200 type: ESTIMATED name: Proactive CPAP Therapy name: Conventional APAP Therapy measure: Adherence measure: Apnea-Hypopnea Index measure: Pressure measure: Self-assessed sleep outcomes measure: Self-assessed functional outcomes sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06319469 id: FMBSUREC/06122022/Mohamed briefTitle: The Additive Value of Pyridostigmine to Silodosin in Acute Urinary Retention overallStatus: COMPLETED date: 2023-02-01 date: 2024-01-30 date: 2024-01-30 date: 2024-03-20 date: 2024-03-20 name: Beni-Suef University class: OTHER briefSummary: Acute urine retention, AUR, is often considered the most serious consequence of aging men with progressive benign prostatic hyperplasia (BPH). AUR is defined as the sudden and painful inability to void freely. This study aims to evaluate whether pyridostigmine bromide added to silodosin is beneficial in treating acute urine retention caused by BPH. conditions: Prostatic Hyperplasia studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 140 type: ACTUAL name: silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet name: silodosin 8 mg capsule measure: International Prostate Symptom Score (IPSS) sex: MALE minimumAge: 50 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beni-Seuf University Hospital city: Banī Suwayf country: Egypt lat: 29.07441 lon: 31.09785 hasResults: False
nctId: NCT06319456 id: APG2575CC301 briefTitle: A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. overallStatus: RECRUITING date: 2024-04 date: 2027-08 date: 2028-08 date: 2024-03-20 date: 2024-04-16 name: Ascentage Pharma Group Inc. class: INDUSTRY briefSummary: This is a global, multicenter, randomized, open-label, Phase III confirmatory study to investigate the efficacy and safety of Lisaftoclax (APG-2575) in combination with Acalabrutinib in patients with newly diagnosed CLL/SLL. conditions: CLL/SLL studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 344 type: ESTIMATED name: Lisaftoclax (APG-2575) name: Acalabrutinib name: Fludarabine name: Cyclophosphamide，CTX name: Rituximab name: Chlorambucil measure: Progress Free Survival (PFS) measure: Objective Response Rate (ORR) measure: Minimal Residual Disease (MRD) negativity rate measure: Safety evaluation based on the adverse event concurrence sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Bengbu Medical College status: NOT_YET_RECRUITING city: Bengbu state: Anhui zip: 233004 country: China name: Yinghua Geng, Ph.D. role: CONTACT name: Yinghua Geng, Ph.D. role: PRINCIPAL_INVESTIGATOR lat: 32.94083 lon: 117.36083 facility: Guangdong Provincial People's Hospital status: NOT_YET_RECRUITING city: Guangzhou state: Guangdong zip: 510080 country: China name: Wenyu Li, Ph.D. role: CONTACT name: Wenyu Li, Ph.D. role: PRINCIPAL_INVESTIGATOR lat: 23.11667 lon: 113.25 facility: Nanfang Hospital of Southern Medical University status: NOT_YET_RECRUITING city: Guangzhou state: Guangdong zip: 510515 country: China name: Xutao Guo, Ph.D. role: CONTACT name: Xutao Guo, Ph.D. role: PRINCIPAL_INVESTIGATOR lat: 23.11667 lon: 113.25 facility: Henan Provincial Cancer Hospital status: RECRUITING city: Zhengzhou state: Henan zip: 450003 country: China name: Keshu Zhou, M.D., Ph.D. role: CONTACT phone: 13674902391 email: drzhouks77@163.com name: Keshu Zhou, M.D., Ph.D. role: PRINCIPAL_INVESTIGATOR lat: 34.75778 lon: 113.64861 facility: Hematology Hospital of the Chinese Academy of Medical Sciences status: RECRUITING city: Tianjin state: Tianjin zip: 300020 country: China name: Lugui Qiu, M.D., Ph.D. role: CONTACT phone: 022-23909272 email: qiulg@ihcams.ac.cn name: Lugui Qiu, M.D., Ph.D. role: PRINCIPAL_INVESTIGATOR lat: 39.14222 lon: 117.17667 hasResults: False
nctId: NCT06319443 id: STUDY00019235 briefTitle: Daily Vinegar Ingestion and 24-Hour Blood Glucose Control overallStatus: RECRUITING date: 2024-03 date: 2024-06 date: 2025-04 date: 2024-03-20 date: 2024-03-20 name: Arizona State University class: OTHER briefSummary: When linking dietary interventions and blood glucose management, much of the existing research - particularly studies exploring the effects of vinegar - has relied on discrete readings from the conventional testing methods: blood samples or glucometers. These methods lack the capacity to provide insights into blood glucose dynamics 24/7.
Recognizing this gap, the current study aims to utilize continuous glucose monitoring to examine the impact of daily vinegar ingestion on glucose variability in adults identified as glucose intolerant. conditions: Glucose Intolerance studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: This is a 9-day trial. Participants will be fitted with a continuous glucose monitor and follow their typical diet and activity patterns. Participants will be randomized to ingest 2 tablespoons of vinegar twice daily (diluted in water) or a vinegar pill for the first 4 days on the trial. On day 5 of the trial participants will consume the alternate treatment for trial days 5-8. Dietary intake will be recorded daily using a fitness app. Physical activity will be assessed at baseline and on study day 4 and 8. On day 9, participants will return to the test site for device removal. primaryPurpose: OTHER masking: SINGLE maskingDescription: Liquid and pill vinegar will be the treatments. The pill is the 'control' as the level of acetic acid is below the amount needed for an antiglycemic effect (a fact not realized by the participant). whoMasked: PARTICIPANT count: 12 type: ESTIMATED name: Liquid vinegar name: vinegar pill measure: Average glucose measure: Glucose: time in range sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: 850 PBC status: RECRUITING city: Phoenix state: Arizona zip: 85004 country: United States name: Carol S Johnston, PhD role: CONTACT phone: 602-965-2539 email: carol.johnston@asu.edu lat: 33.44838 lon: -112.07404 hasResults: False
nctId: NCT06319430 id: HS26236(H2023:343) briefTitle: Technology in Play for Children With Physical Disabilities: the Dice Model of Play overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-04-30 date: 2025-05-28 date: 2024-03-20 date: 2024-03-20 name: University of Manitoba class: OTHER name: Rehabilitation Centre for Children, Canada briefSummary: Play is an important activity for children. Almost all children play, but what is play? It is not easy to define play. In the past, people believed that children played to burn their energy. Now, it is known that play is important for children's growth. Some kids with disabilities cannot play. Many experts use play to teach children specific skills. People often forget that play is a child's right. It is important to help all children play. The first step is to define play and find what features are important in helping a child with a disability play.
There are some models of play. But they are not complete. They do not look at play as a whole. Some models are just about playfulness, and some are about playing with others. Having a model that defines play helps researchers and clinicians think about play and the different parts of it. Then, when a child cannot play, experts can fix the part that is not working. Investigators want to introduce a model of play in this project. Investigators want to edit and complete it in three steps. First, Investigators will ask parents and children with disabilities about things that help or do not help them play; then, investigators will give Lego robots to kids that they will build with help and play with them for a few weeks. And at the end, investigators will ask therapists and other experts about our model of play. This model will be edited during the study. conditions: Physical Disability studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: The primary purpose is validation of.......... primaryPurpose: OTHER masking: NONE count: 10 type: ESTIMATED name: robots name: conventional measure: Test of Playfulness measure: The Child Initiated Pretend Play Assessment (ChIPPA-2) measure: The Pretend Play Enjoyment-Developmental Checklist (PPE-DC) sex: ALL minimumAge: 3 Years maximumAge: 8 Years stdAges: CHILD typeAbbrev: Prot_SAP_ICF hasProtocol: True hasSap: True hasIcf: True label: Study Protocol, Statistical Analysis Plan, and Informed Consent Form date: 2024-01-22 uploadDate: 2024-03-04T16:47 filename: Prot_SAP_ICF_000.pdf size: 1962440 hasResults: False
nctId: NCT06319417 id: HT-UCAM briefTitle: Hydroxytyrosol Caramel Treatment on Cardiovascular Risk Patients overallStatus: COMPLETED date: 2022-04-15 date: 2023-03-23 date: 2023-03-23 date: 2024-03-20 date: 2024-03-20 name: Universidad Católica San Antonio de Murcia class: OTHER briefSummary: The goal of this double-blind crossover randomized clinical trial is to evaluate the impact of a phenolic natural compound called hydroxytyrosol (HT) on patients at cardiovascular risk (CVR). The main questions it aims to answer are:
Participants will take 4 caramels/day, each containing 15 mg of HT, consuming a daily intake of 60 mg for 28 days. One group will begin with HT caramel consumption for 28 days, while the other group will start with a placebo treatment. Following a 2-week washout period, the treatments will be switched between the groups. Those who initially consumed HT will then switch to the placebo treatment, and vice-versa, each for a duration of 28 days. conditions: Cardiovascular Pathology studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: 28 days of treatment: one group with HT treatment and the other with placebo treatment.
2-weeks washout period. The treatment will be switched between groups for another 28 days: those who initially consumed HT will the switch to the placebo treatment, and vice versa. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Nor participant and care provider knew the treatment given. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 26 type: ACTUAL name: HT treatment name: Placebo treatment measure: Change of cardiovascular biomarkers measure: Change of cellular phenotype of platelets sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Catholic University of Murcia (UCAM) city: Murcia zip: 30107 country: Spain lat: 37.98704 lon: -1.13004 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2022-03-01 uploadDate: 2024-03-12T10:59 filename: ICF_000.pdf size: 995478 hasResults: False
nctId: NCT06319404 id: 2022YFC2505700 briefTitle: Immune Function of Colorectal Cancer Lymph Nodes overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-04-01 date: 2026-04-01 date: 2024-03-20 date: 2024-03-20 name: Shanxi Province Cancer Hospital class: OTHER name: The Second Affiliated Hospital of Harbin Medical University name: Cancer Institute and Hospital, Chinese Academy of Medical Sciences briefSummary: Lymph nodes are very important immune organs in the human body and play an important role in the physiological and pathological activities of the body, especially in anti-tumor immunity. The role of regional draining lymph nodes in the development of colorectal cancer is still unknown. In this study, the role of lymph nodes in the development of colorectal cancer was investigated through multicenter and multi-omics data. conditions: Colorectal Cancer conditions: Lymph Node studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 500 type: ESTIMATED measure: To investigate the difference of immune pathway activation in tumor-draining lymph node based on genomics measure: To investigate the relationship between the type and number of immune cells in tumor draining lymph nodes and the activation of immune pathways is based on pathomics measure: The immune function of tumor draining lymph nodes of colorectal cancer patients was previously identified based on radiomics sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06319378 id: CAPSI no 2 date 231024 id: 2023-505532-35-00 type: OTHER domain: CTIS briefTitle: Cancer Related Major Depression Treated With a Single Dose of Psilocybin acronym: CAPSI overallStatus: RECRUITING date: 2024-04-17 date: 2025-12 date: 2025-12 date: 2024-03-20 date: 2024-04-22 name: Section for Affective Disorders; Northern Stockholm Psychiatry class: OTHER name: Uppsala University Hospital name: Region Örebro County name: Vastra Gotaland Region name: Karolinska Institutet briefSummary: The goal of this randomized placebo controlled trial is to compare the antidepressant effect of a single oral dose of psilocybin 25 mg compared to 1 mg in 100 patients with cancer related major depressive disorder. The main question it aims to answer is:
≥10), \>1 month after cancer diagnosis, with at least 12 months of life expectancy, willingness to abstain from other psychotherapeutic or antidepressant treatments during the study (wash out time 5 half-lives). conditions: MDD studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized Controlled Trial, active placebo, randomization ratio 2:1 primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: psilocybin 25 mg sod name: psilocybin 1 mg sod measure: MADRS at day 42 measure: MADRS day 8 measure: MADRS-S at all evaluations between Day 0 and Day 42 (Mixed Models for Repeated Measures (MMRM) x1) measure: SDS at Day 42 measure: CGI at Day 8 and Day 42 (analysis of covariance (ANCOVA) x6) measure: EQ-5D-5L at Day 8 and Day 42 (ANCOVA x6) measure: AQOL-6D at Day 42 (ANCOVA x1) measure: MADRS at Day 90 and Day 180 (ANCOVA x2) measure: MADRS-S at all evaluations between Day 43 and Day 180 (MMRM x1) measure: SDS at Day 180 (ANCOVA x3) measure: GAD-7 at Day 180 (ANCOVA x3) measure: HADS at Day 180 (ANCOVA x3) measure: CGI at Day 90 and Day 180 (ANCOVA x6) measure: EQ-5D-5L at Day 90 and Day 180 (ANCOVA x6) measure: AQOL-6D at Day 90 and Day 180 (ANCOVA x2) measure: GAD-7 at Day 42 measure: HADS at Day 42 sex: ALL minimumAge: 20 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: region Västra Götaland status: RECRUITING city: Göteborg country: Sweden name: Helena Werin Sjögren, MD role: CONTACT email: helena.werin.sjogren@vgregion.se name: Mikael Landén, MD PhD role: PRINCIPAL_INVESTIGATOR lat: 57.70716 lon: 11.96679 facility: Norra Stockholms Psykiatri status: RECRUITING city: Stockholm country: Sweden name: Evana Lopez, MD role: CONTACT email: evana.lopez@ki.se name: Carl-Johan Ekman, PhD role: PRINCIPAL_INVESTIGATOR lat: 59.33258 lon: 18.0649 facility: Psykiatriska Kliniken, Akademiska Sjukhuset status: RECRUITING city: Uppsala country: Sweden name: Evana Lopez role: CONTACT email: evana.lopez@ki.se name: robert Bodén, MD PhD role: PRINCIPAL_INVESTIGATOR lat: 59.85882 lon: 17.63889 facility: Örebro sjukhus status: RECRUITING city: Örebro country: Sweden name: Axel Nordenskjöld, MD PhD role: CONTACT name: Evana Lopez, MD role: CONTACT email: evana.lopez@ki.se name: axel Nordenskjöld, MD PhD role: PRINCIPAL_INVESTIGATOR lat: 59.27412 lon: 15.2066 hasResults: False